Traders should monitor upcoming clinical trial data for CG001419, particularly from the U.S. Phase 2 pain study, and track competitive dynamics in the lung fibrosis space that could impact ETUARY's revenue potential.
Price Chart
Executive Summary
Gyre Therapeutics provided forward-looking guidance at an investor conference, highlighting potential revenue of $400–600 million within five years for its liver fibrosis drug F351 and $100 million for ETUARY in lung fibrosis, along with R&D progress on its TRK degrader CG001419. The disclosure includes no actual financial results but outlines strategic growth opportunities and development updates.
Key Facts
- Potential $400–600 million in revenue within 5 years for liver fibrosis treatment Hydronidone (F351) based on patient population data.
- Expected sustained revenue of ~$100 million for ETUARY in lung fibrosis if no generic competitor enters the market.
- Company anticipates 20%–25% net margins for commercial products and favorable R&D tax deductibility in Beijing and Shanghai.
- 30–40% of current lung fibrosis revenue comes from rheumatoid diseases (RA, lupus, scleroderma, dermatomyositis), expected to sustain or grow.
- Cullgen's Australian cohort validated safety at 400mg for TRK degrader CG001419; U.S. Phase 2 pain trial now enrolling at doses expected to achieve ~95% TRK degradation.
- Degrader antibody conjugates (DAC) show ~10–100x increased potency vs standalone degraders in preclinical models.
- Approximately half of Cullgen's R&D headcount is focused on DAC conjugation, leveraging internal picomolar DC50 compounds across multiple targets.
Financial Impact
Potential future revenues of $400–600 million for F351 and $100 million for ETUARY, with projected 20%–25% net margins; no actual financials reported.
Risk Factors
- All revenue and margin projections are forward-looking and subject to change based on clinical, regulatory, and competitive developments.
- Revenue sustainability for ETUARY depends on absence of generic competition, which is outside the company's control.
- No assurance that preclinical potency advantages of DAC technology will translate into clinical or commercial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-009115 |
| Document: 0001140361-26-009115-index-headers.html | 0001140361-26-009115 |
| Document: 0001140361-26-009115.txt | 0001140361-26-009115 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.85 | awaiting T+20 | — | $6.53 (+11.62%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.53 (+0.93%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.53 (−1.80%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.53 (+2.10%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.53 (+6.18%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.53 (+3.00%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.53 (+17.45%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.53 (−0.31%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers